346 related articles for article (PubMed ID: 18372278)
1. A dynamic comparative study concerning the effects of angiotensin-converting enzyme inhibitors and aldosterone receptor blockers on the fibrinolytic system.
Usalan C; Buyukhatipoglu H
Clin Appl Thromb Hemost; 2008 Apr; 14(2):203-9. PubMed ID: 18372278
[TBL] [Abstract][Full Text] [Related]
2. Effect of combined angiotensin-converting enzyme and aldosterone inhibition on plasma plasminogen activator inhibitor type 1 levels in chronic hypertensive patients.
Tiryaki O; Usalan C; Buyukhatipoglu H
Nephrology (Carlton); 2010 Mar; 15(2):211-5. PubMed ID: 20470281
[TBL] [Abstract][Full Text] [Related]
3. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
[TBL] [Abstract][Full Text] [Related]
4. Function of dynamically stimulated endothelium and renin-angiotensin-aldosterone system in normotensive subjects with a family history of hypertension.
Usalan C; Buyukhatipoglu H; Tiryaki O; Sahin A
Nephrology (Carlton); 2008 Dec; 13(8):689-93. PubMed ID: 19154322
[TBL] [Abstract][Full Text] [Related]
5. Effect of ACE inhibition on the fibrinolytic system in patients requiring coronary artery bypass grafting.
Walter T; Szabo S; Kazmaier S; Suselbeck T; Borggrefe M; Hoffmeister HM
Thorac Cardiovasc Surg; 2009 Sep; 57(6):368-71. PubMed ID: 19707983
[TBL] [Abstract][Full Text] [Related]
6. The renin-angiotensin-aldosterone system and fibrinolysis.
Felmeden DC; Lip GY
J Renin Angiotensin Aldosterone Syst; 2000 Sep; 1(3):240-4. PubMed ID: 11881031
[TBL] [Abstract][Full Text] [Related]
7. Antihypertensive drugs and fibrinolytic function.
Fogari R; Zoppi A
Am J Hypertens; 2006 Dec; 19(12):1293-9. PubMed ID: 17161777
[TBL] [Abstract][Full Text] [Related]
8. Dual blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy: the role of aldosterone.
Schjoedt KJ; Jacobsen P; Rossing K; Boomsma F; Parving HH
Horm Metab Res; 2005 Apr; 37 Suppl 1():4-8. PubMed ID: 15918104
[TBL] [Abstract][Full Text] [Related]
9. Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans.
Brown NJ; Agirbasli M; Vaughan DE
Hypertension; 1999 Aug; 34(2):285-90. PubMed ID: 10454455
[TBL] [Abstract][Full Text] [Related]
10. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition.
van de Wal RM; Plokker HW; Lok DJ; Boomsma F; van der Horst FA; van Veldhuisen DJ; van Gilst WH; Voors AA
Int J Cardiol; 2006 Jan; 106(3):367-72. PubMed ID: 16337046
[TBL] [Abstract][Full Text] [Related]
11. Pharmacology of ACE inhibitors versus AT1 blockers.
Vaughan D
Can J Cardiol; 2000 Aug; 16 Suppl E():36E-40E. PubMed ID: 10906625
[TBL] [Abstract][Full Text] [Related]
12. Questioning a class effect: does ACE inhibitor tissue penetration influence the degree of fibrinolytic balance alteration following an acute myocardial infarction?
Tsikouris JP; Suarez JA; Meyerrose GE; Ziska M; Fike D; Smith J
J Clin Pharmacol; 2004 Feb; 44(2):150-7. PubMed ID: 14747423
[TBL] [Abstract][Full Text] [Related]
13. Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure.
Dieterich HA; Wendt C; Saborowski F
Fiziol Cheloveka; 2005; 31(6):97-105. PubMed ID: 16366159
[TBL] [Abstract][Full Text] [Related]
14. Effects of angiotensin-converting enzyme inhibition on plasma aldosterone concentration, plasma renin activity, and blood pressure in spontaneously hypertensive cats with chronic renal disease.
Steele JL; Henik RA; Stepien RL
Vet Ther; 2002; 3(2):157-66. PubMed ID: 19750747
[TBL] [Abstract][Full Text] [Related]
15. Effects of inhibition of the maternal renin-angiotensin system on maternal and fetal responses to drainage of fetal fluids.
Lumbers ER; Bernasconi C; Burrell JH
Can J Physiol Pharmacol; 1996 Aug; 74(8):973-82. PubMed ID: 8960388
[TBL] [Abstract][Full Text] [Related]
16. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker.
Chrysostomou A; Pedagogos E; MacGregor L; Becker GJ
Clin J Am Soc Nephrol; 2006 Mar; 1(2):256-62. PubMed ID: 17699214
[TBL] [Abstract][Full Text] [Related]
17. Role of the renin-angiotensin-aldosterone system for control of arterial blood pressure following moderate deficit in total body sodium: balance studies in freely moving dogs.
Seeliger E; Lunenburg T; Ladwig M; Reinhardt HW
Clin Exp Pharmacol Physiol; 2010 Feb; 37(2):e43-51. PubMed ID: 19930429
[TBL] [Abstract][Full Text] [Related]
18. The effects of angiotensin-II on lipolysis in humans.
Townsend RR
Metabolism; 2001 Apr; 50(4):468-72. PubMed ID: 11288044
[TBL] [Abstract][Full Text] [Related]
19. The effect of amlodipine and the combination of amlodipine and enalapril on the renin-angiotensin-aldosterone system in the dog.
Atkins CE; Rausch WP; Gardner SY; Defrancesco TC; Keene BW; Levine JF
J Vet Pharmacol Ther; 2007 Oct; 30(5):394-400. PubMed ID: 17803730
[TBL] [Abstract][Full Text] [Related]
20. The effect of enalapril on furosemide-activated renin-angiotensin-aldosterone system in healthy dogs.
Lantis AC; Ames MK; Werre S; Atkins CE
J Vet Pharmacol Ther; 2015 Oct; 38(5):513-7. PubMed ID: 25771846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
